Moreover, loss of tumor suppressor can also be seen in benign Spitz tumors (Quan et al., 2020), suggesting that other somatic alterations, such as the more-common mutations of the TERT promoter or the overall mutational burden, may be better markers of clinical outcomes for these patients (Lee et al., 2015). Here, TERT is linked to neoplasm.